<DOC>
	<DOCNO>NCT02577263</DOCNO>
	<brief_summary>The primary objective trial determine impact FOLFOX regimen quality life incidence chemotherapy induced neurotoxicity .</brief_summary>
	<brief_title>Impact Adjuvant FOLFOX Quality Life Sensory Neurotoxicity Patients With Advanced Gastric Cancer</brief_title>
	<detailed_description>Gastric cancer one main cancer-related cause death world . There one standard treatment non-metastatic advanced disease . Among therapeutic alternative high level evidence recommend surgery follow chemoradiotherapy chemotherapy perioperative chemotherapy . These strategy compare adequate power trial , important regional difference use . Postoperative chemotherapy oxaliplatin base chemotherapy may offer advantage limit resource setting , low logistic requirement could specially useful center high quality surgery . On hand one important downside could higher impact quality life particularly related oxaliplatin induce neuropathy last long end treatment . This prospective observational trial consent subject go evaluate EORTC ( European Organization Research Treatment Cancer ) questionnaires C30 CIPN20 FOLFOX ( 5-fluorouracil/leucovorin oxaliplatin ) adjuvant treatment .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<criteria>Diagnosis gastric adenocarcinoma ECOG ( Eastern Cooperative Oncology Group ) functional status 0 1 Treated surgery curative intent TNM stage II III TNM stage I positives lymph node Surgery microscopical macroscopical residual tumour Adjuvant chemotherapy refusal ECOG functional status 2 Previous peripheral neuropathy Significant cardiovascular disease organ disfunction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>